115 related articles for article (PubMed ID: 14584080)
41. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma.
Sowers R; Toguchida J; Qin J; Meyers PA; Healey JH; Huvos A; Banerjee D; Bertino JR; Gorlick R
Mol Cancer Ther; 2003 Jun; 2(6):535-41. PubMed ID: 12813132
[TBL] [Abstract][Full Text] [Related]
42. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
[TBL] [Abstract][Full Text] [Related]
43. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.
Mauritz R; Peters GJ; Kathmann I; Teshale H; Noordhuis P; Comijn EM; Pinedo HM; Jansen G
Cancer Chemother Pharmacol; 2008 Nov; 62(6):937-48. PubMed ID: 18283461
[TBL] [Abstract][Full Text] [Related]
44. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Hawkins DS; Arndt CA
Cancer; 2003 Dec; 98(11):2447-56. PubMed ID: 14635080
[TBL] [Abstract][Full Text] [Related]
45. Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1).
Hooijberg JH; Jansen G; Assaraf YG; Kathmann I; Pieters R; Laan AC; Veerman AJ; Kaspers GJ; Peters GJ
Biochem Pharmacol; 2004 Apr; 67(8):1541-8. PubMed ID: 15041471
[TBL] [Abstract][Full Text] [Related]
46. [Expression of multidrug resistance-associated protein 1 in osteosarcoma and its relationship with clinicopathologic characteristics].
Tu C; Tian Y; Pei F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 34(4):684-7. PubMed ID: 14619581
[TBL] [Abstract][Full Text] [Related]
47. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
48. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
[TBL] [Abstract][Full Text] [Related]
49. Acquisition of multidrug resistance in osteosarcomas, analyzed by doxorubicin binding assay, and histologic response to chemotherapy.
Kusuzaki K; Hirata M; Hashiguchi S; Takeshita H; Murata H; Ashihara T; Hirasawa Y
Anticancer Res; 1999; 19(6B):5159-62. PubMed ID: 10697527
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma.
Kaseta MK; Khaldi L; Gomatos IP; Tzagarakis GP; Alevizos L; Leandros E; Papagelopoulos PJ; Soucacos PN
J Surg Oncol; 2008 Mar; 97(3):259-66. PubMed ID: 18161867
[TBL] [Abstract][Full Text] [Related]
51. Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier.
Wang Y; Zhao R; Goldman ID
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6256-64. PubMed ID: 15448015
[TBL] [Abstract][Full Text] [Related]
52. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
53. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.
Nozaki Y; Kusuhara H; Endou H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Apr; 309(1):226-34. PubMed ID: 14722319
[TBL] [Abstract][Full Text] [Related]
54. [Effect of high and low doses of methotrexate (MTX) on bone mass in subjects treated for osteosarcoma of the limbs].
Ripamonti C; Avella M; Gnudi S; Figus E
Minerva Med; 1993 Mar; 84(3):131-4. PubMed ID: 8492965
[TBL] [Abstract][Full Text] [Related]
55. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.
de Heer P; Koudijs MM; van de Velde CJ; Aalbers RI; Tollenaar RA; Putter H; Morreau J; van de Water B; Kuppen PJ
Eur J Surg Oncol; 2008 Nov; 34(11):1253-61. PubMed ID: 18556171
[TBL] [Abstract][Full Text] [Related]
56. Survivin expression levels as independent predictors of survival for osteosarcoma patients.
Osaka E; Suzuki T; Osaka S; Yoshida Y; Sugita H; Asami S; Tabata K; Sugitani M; Nemoto N; Ryu J
J Orthop Res; 2007 Jan; 25(1):116-21. PubMed ID: 17034065
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
[TBL] [Abstract][Full Text] [Related]
58. Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma.
Park HR; Jung WW; Bacchini P; Bertoni F; Kim YW; Park YK
Pathol Res Pract; 2006; 202(7):509-15. PubMed ID: 16677779
[TBL] [Abstract][Full Text] [Related]
59. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy.
Zhang L; Taub JW; Williamson M; Wong SC; Hukku B; Pullen J; Ravindranath Y; Matherly LH
Clin Cancer Res; 1998 Sep; 4(9):2169-77. PubMed ID: 9748136
[TBL] [Abstract][Full Text] [Related]
60. Relationship between RFC gene expression and intracellular drug concentration in methotrexate-resistant osteosarcoma cells.
Wang JJ; Li GJ
Genet Mol Res; 2014 Jul; 13(3):5313-21. PubMed ID: 25078587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
